Lupin Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has entered into an exclusive licensing agreement with Valorum for its biosimilar product Armlupeg, which is a version of Pegfilgrastim used to reduce infection risk in cancer patients undergoing chemotherapy. Under this deal, Lupin will likely receive upfront payments, milestone payments, and royalties on sales, while Valorum will handle commercialization in the US market. The agreement gives Valorum exclusive rights to market and distribute this biosimilar in the United States. This move allows Lupin to monetize its biosimilar pipeline without bearing the full cost of US commercialization. It strengthens Lupin's presence in the lucrative US biosimilars market, which is seeing growing acceptance as cost-effective alternatives to expensive biologics.
Positive for shareholders as it validates Lupin's biosimilar portfolio and creates a new revenue stream from the US market without significant upfront investment. Short-term stock impact may be modest, but the deal supports long-term growth in Lupin's specialty/biologics segment.